Skip to main content
Advanced Technical IVT

pyridostigmine

Pronunciation: pie-rid-oh-STIG-meen

Anticholinesterase medication used as first-line symptomatic treatment for myasthenia gravis by improving neuromuscular transmission.

Full Definition

Pyridostigmine is an anticholinesterase inhibitor that serves as the primary symptomatic treatment for myasthenia gravis. The drug works by preventing breakdown of acetylcholine at the neuromuscular junction, thereby enhancing neuromuscular transmission and improving muscle strength. Available in immediate-release and extended-release formulations, pyridostigmine provides temporary symptom relief but does not alter the underlying autoimmune process. Common side effects include gastrointestinal symptoms, increased salivation, and muscle fasciculations due to cholinergic excess. Dosage must be carefully titrated to balance symptom improvement against cholinergic side effects. The medication is also used in other neuromuscular junction disorders and as an antidote for certain nerve agents.

Usage

Usage note: Brand name Mestinon is commonly used; always specify dosage and frequency in prescriptions.

In Context

  • "The patient's myasthenia gravis symptoms improved significantly after initiating pyridostigmine 60mg three times daily." — Treatment response note
  • "Pyridostigmine dosage was adjusted to minimize gastrointestinal side effects while maintaining symptom control." — Medication review

Also known as

Mestinon

Don't confuse with

neostigmine physostigmine

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON